fulltext.study @t Gmail

Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies

Paper ID Volume ID Publish Year Pages File Format Full-Text
23813 43474 2011 13 PDF Available
Title
Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies
Abstract

Parkinson's disease is the most common neurodegenerative movement disorder, affecting about 6 million people worldwide with a slow progression of the symptoms. Its prevalence is expected to double in the most populated areas within the next two decades, according to increasing aged population. Consequently, Parkinson's disease is a socio-economic trouble and a major challenge for the public health system. Parkinson's disease treatment is merely symptomatic, as clinical symptoms appear when about 70% of the involved neurons are lost and potential disease-modifying/neuroprotective therapies would have no effect. In turn, the availability of an objective measure that allows early diagnosis would strongly impact on the costs that biotech- and pharma-companies will sustain in order to develop disease-modifying therapies. The establishment of suitable models to investigate the mechanisms of Parkinson's disease progression and, on the other hand, the discovery and validation of selective and specific molecular biomarkers for early and differential diagnosis are indeed two important goals for a better management of the disease. In this review, we focus on cellular and animal models of Parkinson's disease by describing their advantages and limitations as useful tools to identify pathogenetic pathways that deserve further exploitation. In parallel, we discuss how proteomics may provide a potent tool to observe altered pathways in models or altered biomarkers in patients with an unbiased, hypothesis-free approach.

► Proteomics highlights altered pathways with a hypothesis-free approach. ► Genetic and toxic models of Parkinson's disease shed light on disease mechanisms. ► Clinical trials on new drugs cannot be foreseen without affordable biomarkers.

Keywords
2-DE, two-dimensional electrophoresis; 6-OHDA, 6-hydroxydopamine; CMA, chaperone-mediated autophagy; COR, C-terminal of Roc; CSF, cerebrospinal fluid; DAT, dopamine transporter; DIGE, 2D differential in-gel electrophoresis; EGCG, epigallocatechin 3-gallat
First Page Preview
Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies
Get Full-Text Now
Don't Miss Today's Special Offer
Price was $35.95
You save - $31
Price after discount Only $4.95
100% Money Back Guarantee
Full-text PDF Download
Online Support
Any Questions? feel free to contact us
Publisher
Database: Elsevier - ScienceDirect
Journal: Journal of Biotechnology - Volume 156, Issue 4, 20 December 2011, Pages 325–337
Authors
, ,
Subjects
Physical Sciences and Engineering Chemical Engineering Bioengineering
Get Full-Text Now
Don't Miss Today's Special Offer
Price was $35.95
You save - $31
Price after discount Only $4.95
100% Money Back Guarantee
Full-text PDF Download
Online Support
Any Questions? feel free to contact us